Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Return on Capital Employed came in at 14.54% in Q2 2026, up 1367.0% YoY from 0.99% in Q2 2025, and down 0.5% on a QoQ basis from 14.61% in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 9 years of Return on Capital Employed data on file, last reported at 14.54% in Q2 2026.
- Quarterly Return on Capital Employed rose 1367.0% year-over-year to 14.54% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 14.54% (up 1367.0% YoY) and the FY2025 annual result came in at 14.49%, up 2456.0% from the prior year.
- Return on Capital Employed declined to 14.54% in Q2 2026, from 14.61% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.61% in Q1 2026 to a low of 71.98% in Q1 2022.
- A 5-year average of 6.7% and a median of 3.84% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 8147 bps — and 2024, when it plunged 1531 bps.
- Tracing KNSA's Return on Capital Employed over 5 years: stood at 2.37% in 2022, then slumped by 341 bps to 5.71% in 2023, then sank by 71 bps to 9.76% in 2024, then surged by 232 bps to 12.9% in 2025, then advanced by 13 bps to 14.54% in 2026.
- The last three Return on Capital Employed figures came in at 14.54% (Q2 2026), 14.61% (Q1 2026), and 12.9% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | 14.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.54% |
| Mar 31, 2026 | 14.61% |
| Dec 31, 2025 | 12.90% |
| Sep 30, 2025 | 6.78% |
| Jun 30, 2025 | 0.87% |
| Mar 31, 2025 | -3.21% |
| Dec 31, 2024 | -9.76% |
| Sep 30, 2024 | -5.79% |
| Jun 30, 2024 | -6.16% |
| Mar 31, 2024 | -6.66% |
| Dec 31, 2023 | -5.71% |
| Sep 30, 2023 | -4.47% |
| Jun 30, 2023 | 9.16% |
| Mar 31, 2023 | 5.28% |
| Dec 31, 2022 | 2.37% |
| Sep 30, 2022 | -11.62% |
| Jun 30, 2022 | -61.78% |
| Mar 31, 2022 | -71.98% |
| Dec 31, 2021 | -79.11% |
| Sep 30, 2021 | -74.87% |